Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
AssigneeBiogen Idec Inc.
InventorAaron DEYKIN
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiogen Idec Inc.
InventorAaron DEYKIN
Estimating the term…
The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
A method for treating multiple sclerosis, comprising intramuscularly administering an interferon to a patient once per week, wherein treatment begins with a titration period wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4 and thereafter.
A method for reducing flu-like symptoms associated with administration of an interferon to a patient with multiple sclerosis, comprising:
A titration package for enabling compliance with a regimen of changing dosage of an interferon over a period of time, the package comprising interferon, delivery devices for said interferon, and instructions for intramuscular administration of said interferon by a patient during a titration period, wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4.
Dependencies are inferred from the claim text.